The FDA‐approved macrocyclic peptide CsA has been demonstrated to reverse drug resistance through its modulation of a broad spectrum of multidrug resistance proteins.[43] In this study, we discovered an additional mechanism: CsA can enhance the antitumor efficacy of chemotherapeutic agents by overcoming CypA‐mediated resistance to ferroptosis in NSCLC. This evidence concerns the gene PPIA and non-small cell lung carcinoma.